Objective: Accuracy is recognized as an important attribute of continuous glucose monitors (CGMs). The objective of this research was to understand if improvements in CGM accuracy impact clinical outcomes in patients with T1DM or T2DM.

Research Design and Methods: A review of literature published from January 1999 to June 2017 was conducted using Medline. Articles were included if they reported desired outcome measures of clinical efficacy (HbA1c reduction, time-in-range [TIR], hypoglycemia detection or reduction) regardless of patient diabetes type. Simple linear and multiple regressions were utilized to evaluate the relationship between mean absolute relative difference (MARD) and measures of efficacy.

Results: The literature search yielded 574 results from which 20 articles met the inclusion criteria. MARD for commercialized CGM devices improved, on average, 0.75% per year (R2=0.87, p<0.0001). There was no significant correlation between HbA1c reduction and MARD (coefficient=0.464, R2=0, p=0.8857). A significant relationship was observed between MARD and the detection of hypoglycemic events (coefficient= -0.33, R2=0.63, p<0.0001). Insufficient data was available to assess the correlation between accuracy and TIR or hypoglycemia reduction.

Conclusion: CGM accuracy correlates with an increased detection of hypoglycemic events, but not with HbA1c reduction.
graphic
View largeDownload slide
Disclosure

C.J. Koziel: None. D. Bialonczyk: Employee; Self; Becton, Dickinson and Company. D. Morel: Employee; Self; Becton, Dickinson and Company. J. Petisce: None. D. Saliu: Employee; Self; Becton, Dickinson and Company.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.